🐦 推特Wall St EngineCodex · 实盘不做把握 6/10
北京时间·🕒 发布 07-31 04:08:53时区推断·⟳ 抓取 07-31 04:09:15·⚡ 决策 08-01 04:40:59 +1d00h·87.6 天前
Illumina二季度收入和调整后EPS超预期并上调全年指引
本次财报本身偏正面：Q2收入11.6亿美元高于11.3亿美元预期，调整后EPS 1.31美元高于1.23美元预期，并上调FY26收入和EPS指引。
📄 原文Wall St Engine@wallstengine↗ 原文
ILLUMINA $ILMN Q2’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $1.16B (Est. $1.13B) 🟢; +9.5% YoY 🔹 Adj. EPS: $1.31 (Est. $1.23) 🟢;…
不做 Illumina（ILMN.US）
财报方向偏正面但当前已过7月31日完整交易日，下一可成交窗口到8月3日；且7月30日财报前已放量大涨并创52周新高，上调幅度有限，追多edge不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司提前公告将于2026-07-30美股收盘后发布二季度财报并召开电话会，财报日期本身不是新鲜 surprise。
- 社媒在盘后快速转发财报要点：收入、EPS和全年指引均高于预期。
- 财报发布前的7月30日常规交易中，ILMN已上涨5.27%至205.09美元并创52周新高，成交量高于50日均量，说明财报前预期已有明显交易。市场反应:ILMN 2026-07-30常规盘收涨5.27%至205.09美元。
关键理由
- 本次财报本身偏正面：Q2收入11.6亿美元高于11.3亿美元预期，调整后EPS 1.31美元高于1.23美元预期，并上调FY26收入和EPS指引。
- 但上调幅度不大，FY26收入指引中值约46.2亿美元仅略高于市场预期45.7亿美元，经营利润率指引维持不变，毛利率和自由现金流同比下滑削弱追多质量。
- 当前已是2026-07-31美股收盘后，财报后第一个完整交易日已结束，下一可成交窗口到2026-08-03，财报类短线 surprise 的主要反应窗口已错过。
主要风险
- 行情工具两次504，未能取得7月31日收盘价，但这不是不做主因；核心原因是财报事件已过完整交易日且正向增量幅度有限。
- 公司7月30日财报前一交易日已放量涨5.27%并创52周新高，存在财报预期提前交易的风险。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-07-30 · 影响 weakens
反向因素是非GAAP经营利润率指引维持不变、非GAAP毛利率同比下滑120bp、自由现金流同比下降21%，正向财报质量不够支撑隔日后追多。
检索:Illumina Q2 2026 earnings guidance EPS margin free cash flow 原文 ↗ - 做多前查反向 · 来源 stock_quote · 影响 none
stock_quote两次返回HTTP 504，未取得当前Futu行情；不做结论仍由事件时点和财报edge不足决定。
检索:ILMN.US stock_quote full
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 1,130 字
ILLUMINA $ILMN Q2’26 EARNINGS HIGHLIGHTS
🔹 Revenue: $1.16B (Est. $1.13B) 🟢; +9.5% YoY
🔹 Adj. EPS: $1.31 (Est. $1.23) 🟢; +10% YoY
🔹 ROW Organic Growth: 8.1%
🔹 Non-GAAP Op Margin: 22.5%; -130 bps YoY
Raises FY26 Guide:
🔹 Revenue: $4.60B-$4.64B (Est. $4.57B) 🟢
🔹 Prior Revenue Guide: $4.52B-$4.62B
🔹 Adj. EPS: $5.30-$5.40 (Est. $5.23) 🟢
🔹 Prior Adj. EPS Guide: $5.15-$5.30
🔹 ROW Organic Growth: Greater than 5%; from 2%-4%
🔹 Non-GAAP Op Margin: 23.4%-23.6%; unchanged
Other Q2 Metrics:
🔹 ROW Organic Growth: 8.1%
🔹 Net Income: $207M (Est. $189M) 🟢
🔹 Operating Income: $245M (Est. $246M) 🟡
🔹 Non-GAAP Gross Margin: 68.2%; -120 bps YoY
🔹 Free Cash Flow: $162M; -21% YoY
Comments:
🔸 “Illumina delivered strong results during the second quarter. Momentum continued to build through the first half of 2026, as our technology is enabling clinical customers to expand sequencing-intensive applications. Based on this performance, we are increasing our revenue and earnings guidance for the year.”
🔸 “Demand for NovaSeq X remains high as we expand our workflow and multiomics capabilities, broadening the value of Illumina's ecosystem.”
🔹 Revenue: $1.16B (Est. $1.13B) 🟢; +9.5% YoY
🔹 Adj. EPS: $1.31 (Est. $1.23) 🟢; +10% YoY
🔹 ROW Organic Growth: 8.1%
🔹 Non-GAAP Op Margin: 22.5%; -130 bps YoY
Raises FY26 Guide:
🔹 Revenue: $4.60B-$4.64B (Est. $4.57B) 🟢
🔹 Prior Revenue Guide: $4.52B-$4.62B
🔹 Adj. EPS: $5.30-$5.40 (Est. $5.23) 🟢
🔹 Prior Adj. EPS Guide: $5.15-$5.30
🔹 ROW Organic Growth: Greater than 5%; from 2%-4%
🔹 Non-GAAP Op Margin: 23.4%-23.6%; unchanged
Other Q2 Metrics:
🔹 ROW Organic Growth: 8.1%
🔹 Net Income: $207M (Est. $189M) 🟢
🔹 Operating Income: $245M (Est. $246M) 🟡
🔹 Non-GAAP Gross Margin: 68.2%; -120 bps YoY
🔹 Free Cash Flow: $162M; -21% YoY
Comments:
🔸 “Illumina delivered strong results during the second quarter. Momentum continued to build through the first half of 2026, as our technology is enabling clinical customers to expand sequencing-intensive applications. Based on this performance, we are increasing our revenue and earnings guidance for the year.”
🔸 “Demand for NovaSeq X remains high as we expand our workflow and multiomics capabilities, broadening the value of Illumina's ecosystem.”
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。